Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey

INTRODUCTION: Were the participants of the EMPA-REG OUTCOME trial representative of patients receiving empagliflozin in clinical practice? The aim of the present study was to examine the prevalence of cardiovascular disease (CVD) in type 2 diabetes patients starting empagliflozin treatment in routin...

全面介紹

Na minha lista:
書目詳細資料
發表在:Diabetes Ther
Main Authors: Eliasson, Björn, Ekelund, Jan, Amberntsson, Rikard, Miftaraj, Mervete, Svensson, Ann-Marie
格式: Artigo
語言:Inglês
出版: Springer Healthcare 2019
主題:
Brief Report
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6612325/
https://ncbi.nlm.nih.gov/pubmed/31089969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-0632-4
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍